According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic ...

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...